Deciphera Announces Positive CHMP Opinion for ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
The positive CHMP opinion is a scientific recommendation for marketing authorization and one of the final steps before the European Commission (EC), which has the authority to approve medicines in the European Union (EU), issues a decision on Deciphera's marketing authorization application (MAA) for vimseltinib. This decision is expected in the second quarter of the fiscal year ending March 31, 2026.
'CHMP's positive opinion is an important milestone for the TGCT community in the European Union (EU), where there are currently no approved treatments for TGCT, and for vimseltinib, which is now one step closer to potential EU regulatory approval,' said Ryota Udagawa, President and Chief Executive Officer of Deciphera. 'We look forward to building upon vimseltinib's positive CHMP opinion as we work to bring this medicine to TGCT patients around the world in need of new treatment options.'
The positive CHMP opinion is supported by compelling efficacy and safety results from the pivotal Phase 3 MOTION study of vimseltinib in patients with TGCT not amenable to surgery with no prior anti-CSF1/CSF1R therapy (prior therapy with imatinib or nilotinib allowed), compared to placebo, as well as the Phase 1/2 study of vimseltinib. In MOTION, vimseltinib demonstrated a statistically significant and clinically meaningful objective response rate (ORR) at Week 25 in the intent-to-treat (ITT) population, as assessed by blinded independent radiologic review (BIRR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), versus placebo (40% in vimseltinib arm vs 0% in placebo arm, p <0.0001). The primary endpoint was supported by statistically significant and clinically meaningful improvements in active range of motion, patient-reported physical functioning, and patient-reported pain observed in the vimseltinib arm compared to the placebo arm at week 25. The safety profile of vimseltinib is manageable and consistent with results previously disclosed in the Phase 1/2 clinical trial.
About vimseltinib
Vimseltinib is an oral switch-control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R. Vimseltinib has been developed using Deciphera's proprietary switch-control kinase inhibitor platform. ROMVIMZA™ (vimseltinib) is a kinase inhibitor approved in the United States for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
About Tenosynovial Giant Cell Tumor (TGCT)
TGCT is caused by a translocation in colony-stimulating factor 1 (CSF1) gene resulting in overexpression of CSF1 and recruitment of colony-stimulating factor 1 receptor (CSF1R)-positive inflammatory cells into the lesion. TGCT is a rare, non-malignant tumor that develops inside or near joints. TGCT is caused by dysregulation of the CSF1 gene leading to overproduction of CSF1. TGCT is also known as giant cell tumor of the tendon sheath (GCT-TS) or pigmented villonodular synovitis (PVNS), a diffuse-type of TGCT. TGCT is a locally aggressive neoplasm that can grow and cause damage to surrounding tissues and structures inducing pain, swelling, and limitation of movement of the joint. Surgery is the main treatment option; however, these tumors tend to recur, particularly in diffuse-type TGCT. If untreated or if the tumor continually recurs, damage and degeneration may occur in the affected joint and surrounding tissues, which may cause significant disability. For a subset of patients, surgical resection will potentially cause worsening functional limitation or severe morbidity, systemic treatment options are limited and a new therapeutic option for TGCT is needed.
About Deciphera Pharmaceuticals, LLC
Deciphera, a member of Ono Pharmaceutical Co., Ltd., is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. Deciphera is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from Deciphera's platform in clinical studies, QINLOCK ® (ripretinib) is Deciphera's switch-control kinase inhibitor approved in many countries including the European Union and the United States for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. ROMVIMZA™ (vimseltinib) is a kinase inhibitor approved in the United States for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. For more information, visit www.deciphera.com and follow us on LinkedIn and X (@Deciphera).
About Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of 'Dedicated to the Fight against Disease and Pain,' Ono targets areas with unmet medical needs including oncology, immunology, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company's website at https://www.ono-pharma.com/en.
Cautionary Note Regarding Forward-Looking Statements
In this press release, statements made with respect to current plans, estimates, strategies and beliefs, and other statements that are not historical facts are forward-looking statements about the future performance of the company. These statements are based on current assumptions and beliefs in light of the information currently available and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in the business environment in the pharmaceutical market and amendments to relevant laws and regulations, (ii) disruptions to product supply due to stagnation or delays in production caused by natural disasters, fires, etc., (iii) the possibility that sales activities for new and existing products may not achieve the expected results, (iv) the emergence of new side effects in post-marketing drugs, and (v) infringements of intellectual property rights by third parties. Information about pharmaceutical products included in this press release is not intended to constitute an advertisement or medical advice.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
an hour ago
- Fox News
Common sweetener could hold untapped potential to fight aggressive cancer, study finds
A household sweetener could hold the potential to create an anti-cancer treatment. New research from Hiroshima University in Japan revealed that stevia leaf extract could help fight pancreatic cancer cells. The leaves of the stevia plant (Stevia rebaudiana) are used to make stevia extract, a naturally sweet substance commonly used as a sugar substitute. The study, published in the International Journal of Molecular Sciences, investigated the anti-cancer properties of stevia leaf extract when it is fermented with a certain strain of bacteria. In laboratory research, the fermented extract exhibited "significantly enhanced antioxidant activity and cytotoxicity" against pancreatic cancer cells, the researchers revealed. This led them to believe that this substance could serve as a "promising candidate for pancreatic cancer treatment." Paul E. Oberstein, M.D., medical oncologist and assistant director of the Pancreatic Cancer Center at NYU Langone Perlmutter Cancer Center, shared his thoughts in an interview with Fox News Digital. "This is an interesting study because it evaluated something derived from a natural plant (stevia) and showed that it may have utility in stopping cancer cells from growing in the laboratory," he said. "As the authors point out, the actual stevia plant does not seem to have any benefit for stopping cancer, so they had to use a chemical process to change the plant and make it stronger with a fermentation process." "This is the process of how we discover new treatments – some of which turn out to be absolute game-changers." Oberstein recommended approaching this with caution, as it is unknown whether altering the plant will lead to side effects or toxicity. The study was not performed on humans, so there is "still a lot that's unknown about whether this will help patients," the oncologist added. As stevia extract alone does not have an impact on cancer cells, Oberstein said these findings most likely will not lead to any immediate changes in treatment plans. "The study suggests that if the stevia can be changed in the lab, it may have an impact, so hopefully they will further test this and determine whether this effect happens when tested in people and if it doesn't cause new side effects," he added. "I hope the researchers keep testing this in various formats and in people." Dr. Kristen Arnold, a surgical oncologist and pancreatic cancer specialist at the Orlando Health Cancer Institute, reacted to these study findings in a separate interview with Fox News Digital. "Pancreatic cancer is a very aggressive malignancy," she said. "And we know that even with the most aggressive of therapies, unfortunately, our outcomes are not good." "As a pancreatic cancer community, we spend a lot of time and there's a lot of ongoing effort into trying to find better modalities to treat this disease." Although more research is needed to confirm these preliminary findings, Arnold said she is encouraged by the study. "I think the data's very early to know if it's ultimately going to be a game-changer, but it's very exciting to know that we're finding some positive pre-clinical data," she said. "This is the process of how we discover new treatments – some of which turn out to be absolute game-changers and make dramatic changes in the lives of our patients." "Not all of it pans out, but it's a process of discovery," Arnold added. For those with pancreatic cancer, Arnold recommends seeking out appropriate clinical trial opportunities as new science develops. "The clinical trials are ultimately what determine how we treat patients on a day-to-day basis," she added. Fox News Digital reached out to the study authors for comment.
Bloomberg
2 hours ago
- Bloomberg
Ukraine Aims to Get All EU Financial Aid Planned for This Year
Ukraine plans to get its European reform program back on track after missed deadlines prompted the European Union to cut financial aid disbursements, said Economy Minister Oleksii Sobolev. The war-torn country wants to get €12.5 billion ($14.5 billion) from the European Union under the Ukraine facility, the financial support mechanism that aims to help keep the economy afloat amid the full-scale Russian invasion well into its fourth year.
Yahoo
5 hours ago
- Yahoo
Pound dips and dollar higher as traders weigh new tariffs
Pound (GBPUSD=X, GBPEUR=X) The pound dipped against the dollar and euro on Friday to start off August, as it capped off its worst monthly loss since Liz Truss's mini budget. Traders are now looking to the latest purchasing manufacturers index (PMI) reading for more clues on the health of the UK economy, as growth worries linger. Sterling (GBPUSD=X) fell below the $1.32 mark, pulling 0.1% lower in the morning session. Over the past five days it is 1.9% lower against the greenback. Alongside new data, fresh tariffs from the US are firmly on the radar, spelling more uncertainty for the global economy. Friday marks Trump's self-imposed deadline for some US trade deals. Notably, Canada faces a 35% tariff via a new executive order – an increase from the 25% previously imposed. Prime minister Mark Carney said he was "disappointed" with the policy, however many goods subject to the trade rules have already been exempted from those costs under a previous deal. The UK struck a deal with the US in May, however the terms are not yet set in stone, with steel tariffs still a question mark. The US dollar index ( which tracks the greenback against a basket of six currencies, was little changed at around the 100 mark. Meanwhile, the pound was trading at 1.15 against the euro ahead of the EU's consumer price inflation release. Gold (GC=F) Gold prices dipped slightly on Friday, pulling back from the previous day's gains as traders look to key data from the US later today, including the jobs report. The yellow metal lost ground amid a stronger dollar and dampened hopes for a US Federal Reserve rate cut. Gold futures (GC=F) fell 0.3% to $3,340 per ounce at the time of writing, while spot gold was down 0.1% to $3,286 per ounce. Markets will be looking for guidance on today's essential CPI flash estimate of non-farm payrolls data and wage increases prints in confirming or challenging such gold bullish narrative," said Mohammed Taha from forex trading firm MH Markets. "A weak-side surprise by inflation and labour data, however, can hasten policy easy expectations and push through additional gains. Upside surprises can, on the other hand, give temporary consolidation. "But downbeat worries of inflation stickiness, labour frailty, and global trade policy change persist and continue to justify gold as an always-applicable strategic hedge within diversified client holdings." Oil (BZ=F, CL=F) Oil futures rose on Friday, after falling more than 1% in the previous session with tariffs playing heavily on traders' minds. Brent crude (BZ=F) futures rose about 0.2% to around the $71.88 per barrel mark, while West Texas Intermediate (WTI) futures (CL=F) rose slightly to trade at $69.42 a barrel. Brent (BZ=F) is up more than 5% for the week and WTI (CL=F) has staged a more than 6.5% gain over the past five sessions. Oil has been volatile with concerns around supply emanating out of potential changes in trade policy. There are worries that new trade restrictions and higher tariffs could suppress global growth, which would mean economies use less oil. JP Morgan (JPM) analysts said in a note on Thursday Trump's warnings to China and India of penalties on their ongoing purchases of Russian oil potentially puts 2.75 million barrels per day of Russian seaborne oil exports at risk, Reuters reported. "The Trump administration, like its predecessors, will likely find sanctioning the world's second-largest oil exporter [Russia] unfeasible without spiking oil prices," the analysts in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
